GlassScriptPhysician profile
Saikrishna Patibandla
NPI 1750813879
$2,832.71
in general payments reported to CMS, 2019-2025
13 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $851 · 2023: $844 · 2024: $683 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $785.71 | 2022-2025 | General Therapies Ep, Accolade Sr |
| Medtronic, INC. | $679.32 | 2023-2024 | Linq II, Azure Xt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.66 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $195.47 | 2024-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $174.12 | 2022-2023 | |
| Esperion Therapeutics, INC. | $141.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $112.96 | 2024-2025 | |
| Amgen INC. | $82.10 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $55.35 | 2023-2025 | |
| Biotronik INC. | $54.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.47 | 2021-2025 | Farxiga |
| Daiichi Sankyo INC. | $25.47 | 2024 | Injectafer |
| Atricure, INC. | $22.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saikrishna Patibandla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.